Company
Alliance Pharma PLC
LON:APH
Alliance Pharma PLC is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries. The company holds marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential.
156 stories · page 1 of 8
UK CMA launches High Court disqualification order against Alliance Pharma CEO
Alliance said it "did not participate in, or profit from, any market sharing arrangement and refutes any involvement by the company" or its CEO Peter Butterfield
Archive
Market Movers: Instem advances after $12mln contract win
A look at some risers and fallers in the market on Friday.
Alliance Pharma saw strong first-half performance
"We expect the group's strong performance will continue throughout the second half and anticipate this will have a positive impact on cash generation,” said Peter Butterfield
Alliance Pharma appoints top Walgreens-Boots-Alliance manager as non-executive director
Kristof Neirynck will join as an independent non-executive director in December
Alliance Pharma chairman says integration of Biogix and Amberen is largely complete
David Cook provided the short update ahead of the company's AGM later Wednesday
Alliance Pharma's impressive consumer healthcare playbook underrated says RBC
Almost three-quarters of Alliance’s revenues now come from consumer healthcare with superior growth
Alliance Pharma triples dividend as it integrates Biogix acquisition and eyes others
"Whilst our near-term focus will be on integrating Biogix into our existing US business, we will continue to look for opportunities to selectively add to our portfolio," said chief executive Peter Butterfield
Archive
ADM Energy jumps on news of possible fundraising and Nigerian investment
A look at the major movers on the London stock market on Thursday
Alliance Pharma says profit to be marginally ahead of forecasts despite coronavirus pandemic challenges
The healthcare products firm also said its cash flow in 2020 has "remained very strong", bolstered by favourable movements in net working capital
Alliance Pharma beefs up US arm with menopause treatment supplement
Amberen is expected to become Alliance's second-largest brand
Alliance Pharma holds dividend as recovery from coronavirus disruption continues
The company’s flagship consumer healthcare brands were helped by a strong performance from scar prevention treatment Kelo-cote
Alliance Pharma starting to see some good signs of recovery
The disruption caused by the coronavirus pandemic has had an effect on revenues but things have been picking up of late, especially in China
Alliance Pharma rises as consumer confidence returns to Chinese market
CEO Peter Butterfield also said the company had not experienced “any significant supply disruption” due to the coronavirus pandemic
Alliance Pharma delivers strong set of prelims
In common a growing band of businesses it has decided to pass on the dividend in order to conserve cash
Alliance Pharma looks to second half recovery in Asia
The group's supply chain is holding up well, Alliance said
Alliance Pharma firing on all cylinders as revenues grow 16% and net debt tumbles
The stand-out performer, growing 38%, was scar reduction treatment Kelo-cote